Q4 Earnings Estimate for TG Therapeutics Issued By B. Riley

Key Points

• Analysts at B. Riley have increased their Q4 2025 earnings per share estimate for TG Therapeutics to $0.36, up from $0.34, while the consensus estimate for the current full-year earnings is $0.08 per share.
• Despite a quarterly earnings miss with reported EPS of $0.17, TG Therapeutics experienced a significant year-over-year revenue increase of 92.1%.
• Shares of TG Therapeutics have a current market cap of $4.51 billion, with a consensus rating of "Moderate Buy" and a price target of $43.80.

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - B. Riley lifted their Q4 2025 EPS estimates for TG Therapeutics in a research report issued to clients and investors on Monday, August 4th. B. Riley analyst M. Mamtani now anticipates that the biopharmaceutical company will earn $0.36 per share for the quarter, up from their previous estimate of $0.34. The consensus estimate for TG Therapeutics' current full-year earnings is $0.08 per share. B. Riley also issued estimates for TG Therapeutics' FY2026 earnings at $1.34 EPS, FY2027 earnings at $2.38 EPS, FY2028 earnings at $3.52 EPS and FY2029 earnings at $4.42 EPS.

Separately, The Goldman Sachs Group upgraded shares of TG Therapeutics to a "hold" rating and set a $37.00 target price for the company in a research report on Thursday, July 10th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, TG Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $46.25.

TG Therapeutics Price Performance

TG Therapeutics stock traded down $1.18 during trading hours on Wednesday, hitting $26.71. The stock had a trading volume of 4,790,083 shares, compared to its average volume of 2,380,766. The stock has a market capitalization of $4.24 billion, a price-to-earnings ratio of 72.19 and a beta of 1.95. The company has a debt-to-equity ratio of 1.03, a current ratio of 4.02 and a quick ratio of 3.04. TG Therapeutics has a 1-year low of $19.45 and a 1-year high of $46.48. The stock's fifty day moving average is $36.10 and its two-hundred day moving average is $35.95.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.15). The firm had revenue of $141.15 million during the quarter, compared to analysts' expectations of $147.76 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 27.83%. The business's revenue for the quarter was up 92.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.04 earnings per share.

Insider Transactions at TG Therapeutics

In other news, Director Yann Echelard sold 10,000 shares of the company's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $36.94, for a total transaction of $369,400.00. Following the completion of the transaction, the director owned 228,816 shares of the company's stock, valued at $8,452,463.04. This represents a 4.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 10.64% of the company's stock.

Institutional Investors Weigh In On TG Therapeutics

Several hedge funds have recently modified their holdings of the stock. Rockefeller Capital Management L.P. acquired a new position in shares of TG Therapeutics in the 2nd quarter valued at $420,000. SG Americas Securities LLC raised its position in shares of TG Therapeutics by 190.2% in the 2nd quarter. SG Americas Securities LLC now owns 9,289 shares of the biopharmaceutical company's stock worth $334,000 after buying an additional 6,088 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in TG Therapeutics by 1,221.4% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 422,078 shares of the biopharmaceutical company's stock valued at $15,191,000 after acquiring an additional 390,137 shares during the last quarter. Police & Firemen s Retirement System of New Jersey boosted its holdings in TG Therapeutics by 10.7% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 32,914 shares of the biopharmaceutical company's stock valued at $1,185,000 after acquiring an additional 3,174 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in TG Therapeutics by 6.3% during the second quarter. Geode Capital Management LLC now owns 3,490,457 shares of the biopharmaceutical company's stock valued at $126,033,000 after acquiring an additional 207,890 shares during the period. 58.58% of the stock is owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.